BioNTech SE · NASDAQ:BNTX
BioNTech — Shareholder Meeting (May 2023)
38 slides from BioNTech's shareholder meeting presentation, May 25, 2023
Slide 1: Annual General Meeting May 25, 2023
May 25, 2023 Annual General Meeting English Convenience Translation: German language is the official version. Exhibit 99.2
Slide 2: Management Report Agenda No. 1
Financial Development 2022 / Q1 2023 and Financial Outlook 2023 Jens Holstein, Chief Financial Officer2 1 Operations Development 2022 / Q1 2023 and Operations Outlook 2023 Prof. Dr. Ugur Sahin, Chief Executive Officer & Founder MANAGEMENT REPORT AGENDA NO. 1
Slide 3: Operations Development 2022 & Q1 2023 and Operations Outlook 2023
1 Operations Development 2022 & Q1 2023 and Operations Outlook 2023 Prof. Dr. Ugur Sahin, CEO & Founder
Slide 4: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to
Slide 5: COMIRNATY authorization in the EU
COMIRNATY® ▼(the Pfizer-BioNTech COVID-19 vaccine) has been granted standard marketing authorization (MA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in the population aged 6 months and older. In people from 5 years of age and older the vaccine is administered as a 2-do
Slide 6: Authorized Use in the U.S. COMIRNATY
AUTHORIZED USE IN THE U.S. COMIRNATY® (COVID-19 Vaccine, mRNA) • COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 yea
Slide 7: Our Vision
OUR VISION USING THE FULL POTENTIAL OF THE IMMUNE SYSTEM TO DEVELOP NEW IMMUNOTHERAPIES AND VACCINES
Slide 8: BioNTech Today
BioNTech Today 8 Global organization on 5 continents Presence in Europe, North America, Africa, Asia and Australia Broad pipeline across 4 drug classes mRNA vaccines, small molecule immunomodulators, cell therapies and protein-based therapeutics Expertise in the production of mRNA therapeutics and c
Slide 9: Vision: A Global Next-Generation Immunotherapy Company
Vision: A Global Next-Generation Immunotherapy Company 9 INNOVATIVE AND DIVERSIFIED PIPELINE Develop potent and precise medicines to address diseases with high unmet medical need. INNOVATION AT SCALE We want to establish dedicated organizational structures that foster holistic growth. HEALTHCARE AND
Slide 10: Advancing Towards Our Vision
10 *Excluding studies with Comirnaty. IND = Investigational new drug; FIH = First-in-human. Advancing Towards Our Vision Infectious diseases 6 Phase 2 trials Globally first-to-market BA.4-5-adapted COVID-19 vaccine 7 programs in 8 clinical trials* 20 programs in 25 clinical trials Deepen COVID-19 va
Slide 11: BioNTech Achievements in 2022 & 2023
BioNTech Achievements in 2022 & 2023 11 Goal: To deliver long-term value to patients, shareholders, and society Launch of variant- adapted vaccine and further label expansion Development of advanced oncology programs and expansion of early-stage pipeline Ramped up R&D investment and made strategic i
Slide 12: 2022 & 2023: Global Growth
2022 & 2023: Global Growth 12 Memorandum of Understanding for new collaboration Local cooperation BioNTech site2 Manufacturing site2 United Kingdom Collaboration with UK government with the target to deliver personalized therapies to up to 10,000 patients by end of 2030 Israel Pandemic preparedness
Slide 13: Global Social Responsibility at Our Core
13 Global Social Responsibility at Our Core 13 Democratizing Access to Novel Medicines and Upholding Social Responsibility COVID-19 vaccine delivery to LMICs • 1.7 billion doses of COVID-19 vaccine in total to low- and middle-income countries (LMICs) delivered in line with demand2 For diseases with
Slide 14: COVID-19 Vaccine Global Leadership
COVID-19 VACCINE GLOBAL LEADERSHIP
Slide 15: 2022: Continued Leadership against COVID-19
2022: Continued Leadership against COVID-19 15 1 Partnered with Pfizer 2 As of Dec. 16, 2022 3 Pfizer/BioNTech cumulative global COVID-19 market share across reporting countries; CDC, ECDC OWID data as of Nov 2022 4 in the U.S., EU and United Kingdom Invoiced ~2 billion doses of vaccine Shipped ~550
Slide 16: COVID-19 Franchise: Building for Continued Success
COVID-19 Franchise: Building for Continued Success 16 Comprehensive COVID-19 research program Ability to rapidly roll out new vaccines at commercial scale within months Investments in combination vaccines and next- generation COVID-19 vaccines Leveraging AI and ML for pandemic preparedness Developme
Slide 17: Deaths and Hospitalizations due to COVID-19 and Flu (2022)
Deaths and Hospitalizations due to COVID-19 and Flu (2022) 17 1. WHO Coronavirus (COVID-19) Dashboard; 2. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html; 3. Portmann et al. Jama Netw Open. 2023; 4. Huerne K. Am J Med Open. 2023; 5. Davis H et al. Nature Reviews Microbiolog
Slide 18: Diversified Product Pipeline
DIVERSIFIED PRODUCT PIPELINE
Slide 19: Technology Agnostic Innovation Engine
Technology Agnostic Innovation Engine 19 1 mRNA encoded cancer-targeting antibodies and cytokines. AI = Artificial intelligence; CAR = chimeric antigen receptor; TLR = Toll-like receptor; TCR = T cell receptor; STING = stimulator of interferon genes. AI & Machine Learning – Internal capabilities & I
Slide 20: Long-Term Strategy: Expand Treatment Options for Solid Tumor Patients
Long-Term Strategy: Expand Treatment Options for Solid Tumor Patients 20 1. Partnered with Genentech, member of Roche Group; 2. Partnered with Genmab; 3. Partnered with DualityBio; 4. Partnered with OncoC4. ADC = antibody-drug conjugate. mRNA-cancer- vaccines Cell therapies ADCs Next-Generation chec
Slide 21: Oncology Pipeline
Oncology Pipeline 21 1. Investigator-initiated / Investigator-initiated and sponsored trial; 2. Partnered with Genentech, member of Roche Group; 3. Partnered with Sanofi; 4. Partnered with Genmab; 5. Partnered with OncoC4; 6. Partnered with DualityBio. NSCLC = Non-small cell lung cancer; HPV = Human
Slide 22: Infectious Diseases: Important Growth Area
Infectious Diseases: Important Growth Area Addressing High Medical and Global Health Need 22 Ongoing clinical programs: All figures from World Health Organization (WHO) factsheets. https://www.who.int/news-room/fact-sheets (accessed April 14, 2023). 1.Partnership with Pfizer; 2. Cooperation with PFE
Slide 23: Infectious Disease Pipeline
Phase 1 BNT162b2 (Original/Omicron BA.4-5-adapted bivalent)1 COVID-19 Pfizer Partnered Programs COMIRNATY1 COVID-19 BNT162b2 (Original/Omicron BA.1-adapted bivalent)1 COVID-19 BNT162b51 (Enhanced spike antigen) COVID-19 BNT162b4 + BNT162b21 (T-cell enhancing) COVID-19 BNT1633 HSV-2 Infectious Diseas
Slide 24: Outlook 2023
OUTLOOK 2023 BIONT=CrH
Slide 25: 2023 Strategic Priorities
Immuno-oncology Infectious diseases 2023 Strategic Priorities 1. In Partnerschaft mit Pfizer, 2. In Kooperation mit PFE und vorbehaltlich der Vereinbarung mit unseren Partnern, 3. In Partnerschaft mit Genentech, Teil der Roche Gruppe, 4. In Partnerschaft mit Genmab, 5. In Partnerschaft mit OncoC4, 6
Slide 26: Financial Development 2022 & Q1 2023 and Financial Outlook 2023
2 Financial Development 2022 & Q1 2023 and Financial Outlook 2023 Jens Holstein, CFO
Slide 27: Highlights in FY 2022
Highlights in FY 2022 27 R&D expenses guidance $1.3bn €1.5bn€16 - 17bn €0.5bn COVID-19 vaccine revenues guidance Share repurchase program spending Dividend
Slide 28: Key financial figures for FY 2022
Key financial figures for FY 2022 28 1. BioNTech's share of profit is estimated as further described in the 2022 Annual Report based on preliminary data exchanged between Pfizer and BioNTech. Any changes in the estimated share of the collaborator's gross profit are recorded prospectively; 2. The pay
Slide 29: FY 2022 Guidance vs. Actuals
29 FY 2022 Guidance vs. Actuals 1. BioNTech's share of profit is estimated as further described in the 2022 Annual Report based on preliminary data exchanged between Pfizer and BioNTech. Any changes in the estimated share of the collaborator's gross profit are recorded prospectively; 2. Reduction in
Slide 30: FY 2022 Financial Results – Profit and Loss
30 FY 2022 Financial Results – Profit and Loss 1. Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the consolidated statements of profit and loss has been condensed; 2. BioNTech's share of profit is e
Slide 31: Q1 2023 Key Highlights
31 Q1 2023 Key Highlights 1. BioNTech's share of profit is estimated as further described in the 2022 Annual Report based on preliminary data exchanged between Pfizer and BioNTech. Any changes in the estimated share of the collaborator's gross profit are recorded prospectively; 2. Consists of cash a
Slide 32: Q1 2023 Financial Results – Profit and Loss
32 Q1 2023 Financial Results – Profit and Loss 1. Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the unaudited interim consolidated statements of profit and loss has been condensed; 2. BioNTech's sh
Slide 33: FY 2022 and Q1 2023 Return to Shareholders
33 FY 2022 and Q1 2023 Return to Shareholders 1. For the share repurchase, the "percentage of share capital" ratio is calculated based on the shares issued as of April 30, 2022 (248,552,200 ordinary shares). 2022: Dividend for FY 2021 Period Number of acquired ADSs Percentage of share capital1 Avera
Slide 34: 1. The "share of issued share capital" ratio is calculated on the basis of
34 1. The "share of issued share capital" ratio is calculated on the basis of the shares issued as of the respective fulfillment period; 2. Sec.186 para. 3 sent. German Stock Corporation Act (Aktiengesetz); 3. The ordinary shares were issued in U.S. dollars; the amounts represent the issue amount ag
Slide 35: FY 2023 Financial Guidance Key Assumptions and Considerations
FY 2023 Financial Guidance 35 Key Assumptions and Considerations Expected increase in demand for a new, adapted vaccine with a simultaneous reduction in the number of primary and booster vaccinations. Assumption of seasonal demand, majority of revenues expected in second half of 2023. Expected trans
Slide 36: 2023 FY Guidance Reiterated
2023 FY Guidance Reiterated1 36 COVID-19 vaccine revenues for FY 2023 Estimated BioNTech COVID-19 vaccine revenues ~ €5 bn Planned FY 2023 expenses and capex R&D expenses2 €2,400 – 2,600 m SG&A expenses €650 – 750 m Capital expenditure for operating activities3 €500 – 600 m Estimated FY 2023 tax ass
Slide 37: FY 2023 Capital Allocation Framework
37 FY 2023 Capital Allocation Framework R&D activities M&A and business development Main focus remains on the acceleration of our R&D activities in oncology and infectious diseases. Strengthen pipeline, technology platforms and digital capabilities by collaborations and potential complementary M&A.
Slide 38: Thank you
Thank you BIONT=CrH